Sichuan Kelun-Biotech
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Sichuan Kelun-Biotech Biopharmaceutical (HKEX: 6990) is a Chengdu-based antibody-drug-conjugate (ADC) developer founded in 2016 as an innovation arm of Kelun Pharmaceutical. Its core asset is SKB264 (sacituzumab tirumotecan, sac-TMT), a TROP2-directed ADC partnered globally with MSD/Merck, and the company went on to list on the Hong Kong Stock Exchange in July 2023 as one of China's leading ADC biotechs.
02 / Sichuan Kelun-Biotech FAILURE REASONS
Failure reasons
The reported failure was financial, not operational: the company's 2023 annual results, published in March 2024, fell badly short of analyst expectations - revenue of CN¥1.5 billion missed consensus while the statutory loss of CN¥2.80 per share came in 89% larger than predicted. Analysts cut their 2024 revenue forecasts by roughly a quarter and raised loss estimates, and the company remained loss-making through 2024 and 2025 despite growing product revenue.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Sichuan Kelun-Biotech is founded in Chengdu as the innovative-drug arm of Kelun Pharmaceutical, focused on ADC and biologic drug development.
- MSD partnership
Kelun-Biotech licenses its TROP2 ADC SKB264 to MSD/Merck, a landmark global collaboration that later drives milestone-driven revenue.
- Hong Kong listing
The company lists on the Hong Kong Stock Exchange (stock code 6990), raising capital to fund its ADC pipeline.
- Annual results miss
Kelun-Biotech publishes its 2023 annual results in March 2024: revenue of CN¥1.5 billion misses expectations and the statutory per-share loss of CN¥2.80 is 89% larger than analysts predicted. In August 2024 the NMPA accepts the second new-drug application for sac-TMT and grants priority review.
- Results and legal settlement
The company reports 2024 revenue of RMB 1,933 million, up 25.5%, with the annual loss narrowing to RMB 266.8 million; in December 2025 it settles its trade-secret dispute with former executives' MediLink Therapeutics, securing revenue sharing on six ADC pipelines.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
For 2023, Kelun-Biotech reported revenue of about CN¥1.5 billion, below analyst expectations, with a statutory loss of CN¥2.80 per share - 89% larger than predicted.
- 02
For 2024, revenue grew 25.5% to RMB 1,933.0 million, gross profit rose 67.8% to RMB 1,273.7 million, and the annual loss narrowed to about RMB 266.8 million (roughly $37 million).
- 03
For 2025, the annual loss widened again to RMB 382 million as commercialization spending surged, while operating cash flow stayed negative.
- 04
The company has funded itself through its 2023 IPO and repeated H-share placements, with cash and financial assets of about RMB 4.56 billion at end-2025.